CLAL INDUSTRIES
CLAL Biotechnology Industries (CBI) is the largest life sciences investment company traded on the Tel Aviv stock exchange (TASE: CBI). CBI focuses on promising innovative ventures, developing proprietary solutions, and addressing unmet medical needs with significant market potential. With offices in Tel-Aviv and Boston, CBI provides their portfolio companies access to the global biotechnology industry. Based on top Israeli science, their portfolio companies range from seed to maturity, both public and private. CBI applies diverse models of strategic cooperation, providing hands-on leadership and guidance.
Successful portfolio firms include MediWound (Nasdaq: MDWD), biotechnology focused on severe burn and chronic wound management; Elicio, technologies that deliver agents directly to the antigen-presenting cells of the lymph nodes; Sight Diagnostics, uses computer-vision and machine learning technology in blood diagnostics; Colospan, developing a medical device to alleviate the clinical and economic burden of anastomotic leaks following colorectal procedures; Biokine, developing therapeutics to treat cancer. Its lead product, motixafortide is licensed to BiolineRx and is in phase III clinical development; and Pi-Cardia, developing a minimally invasive treatment of patients with life threatening heart valve disease.
CLAL actively pursues relevant expansion opportunities in the local and global marketplace. CLAL’s activities are conducted through subsidiaries, jointly controlled entities, affiliates, and other companies. The company prioritizes activities which strengthen ties with existing and potential strategic partners in Israel, and which expand its operations, or those of its portfolio companies, internationally.
Ofer Gonen, Chief Executive Officer at CBI, has managed the company’s life science investments and business development in both the US and Israel since 2017. Previously, Mr. Gonen served as the Vice President of CBI from 2003-2015. Mr. Gonen serves as a Board Member of several portfolio companies, including Gamida Cell (Nasdaq: GMDA) and MediWound (Nasdaq: MDWD). Prior to joining CBI, Ofer was the General Manager of Biomedical Investments Ltd., a partner at Arte Venture Group, as well as a technology consultant to various Israeli venture capital funds. Mr. Gonen gained extensive experience in R&D and management of defense-oriented projects within the prestigious “Talpiot” program of the Israeli Defense Forces, for which he was awarded the Israeli National Security Medal. Mr. Gonen holds a B.Sc. in Physics, Mathematics and Chemistry from the Hebrew University of Jerusalem, and an M.A. in Economics and Finance from Tel Aviv University, with distinction.
Learn more at http://clalindustries.com/